Name: Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity (Video) | JoVE Journal
Uploaded: 2025-01-31T12:00:00.000+00:00
Duration: 9 min 38 s
Description: Learn minimally invasive isolated limb perfusion for treating advanced melanomas and sarcomas of the extremity using localized high-dose chemotherapy. This protocol demonstrates percutaneous vascular access and perfusion techniques.

ai_agent_IP

ai_agent

maintenance

instantTrialDurationMinutes

isBiopharma

enableNewMyJoveSectionDesign

educationFeatures

seoMetaApi

ai_copilot_institution_blacklist

ai_chat_institution_blacklist

freeAccessWindow

ssoRoleCapture

scheduledMaintenanceBanner

joveLabsFeatures

disable_autoplay_for_bots

extended_trial_duration

5 minutes

Polle Willemsen (filmer and producer) is acknowledged for excellent video recording and editing of the movie.

The protocol adheres to the guidelines established by our Institution&#39;s Human Research Ethics Committee.
1. Anesthesia
<ol>
	<li>Induce anesthesia according to the Institute&#39;s local protocol.</li>
</ol>
2. Set up
<ol>
	<li>Calculate the leg volume of the patient (1 day preoperative):
	<ol>
		<li>Lay the patient supine and draw a circular baseline starting in the groin. With 5 cm intervals, mark the patient&#39;s leg down to the ankle.</li>
		<li>If there is evidence of tumor load in the foot, include foot measurements by adding the length from the heel of the patient to the end of the first toe and the end of the fifth toe.</li>
		<li>Add all measurements in a spreadsheet with an underlying calculation model that summed the calculation of cones at the predefined levels of 5 cm.</li>
	</ol>
	</li>
	<li>Place a scintillation probe above the heart of the patient to enable capturing the percentage of leakage to the systemic circulation under the perfusion period.</li>
	<li>Inject a small dose of 10 MBq Tc99m marked albumin. To calculate the biological half-time, the activity is then measured for at least 20 min.</li>
</ol>
3. Femoral access
<ol>
	<li>Localize the superficial femoral or brachial vein using ultrasound guidance. Make a small 5 mm incision with a scalpel in the skin. Puncture the superficial artery first with a special needle (20 G, 12 cm) at approximately 15 cm below the inguinal ligament and place a 0.018&#34; introducer guidewire.</li>
	<li>Place a micro-introducer (4 French, 10 cm).</li>
	<li>Remove the 0.018&#34; introducer guidewire and the inner dilator.</li>
	<li>Introduce a 0.035&#34; exchange guidewire via the 4 French introducer and verify its position by fluoroscopy.</li>
	<li>Perform adequate predilation of the entry tract with several dilators over the exchange wire.</li>
	<li>After sufficient pre-dilatation, introduce a 12-14 Fr minimally invasive cannula and place it over the exchange wire into the vein. Flush the venous catheter with heparin saline. Then secure it with a skin suture.</li>
	<li>Cannulate slightly proximal to the venous level, in a similar fashion, the superficial femoral artery.</li>
	<li>Puncture the artery with a 20 G angiography needle and place a 0.018&#34; introducer guidewire.</li>
	<li>Remove the needle and place a 10 cm long 4 Fr mini access introducer over the wire. Remove both the guidewire and the inner dilator of the introducer.</li>
	<li>Confirm vascular access by aspirating blood via the introducer, as well as, hand injection of a small dose of iodinated contrast under fluoroscopy.</li>
	<li>Introduce a 0.035&#34; exchange wire via the 4 French introducer and verify its position by fluoroscopy. Remove the introducer.</li>
	<li>Place with a pre-closing technique two ProGlide sutures. Place the first one at the 10 o&#39;clock position and the other at the 2 o&#39;clock position. Do not tighten the sutures, but clamp the suture limbs slightly away from the puncture site.</li>
	<li>Place a 10-12 Fr minimal invasive cannula over the guidewire into the superficial femoral artery.</li>
</ol>
4. Isolating the leg
<ol>
	<li>Connect the arterial and venous catheters to the perfusion system, which consists of a heart-lung machine equipped with a pump, heat exchanger, oxygenator, and volume reservoir.</li>
	<li>Isolate the limb by applying two Esmarch tourniquets around the limb, proximal to the catheters.</li>
	<li>Remove the clamps from the arterial and venous cannulas to the shunt site. Start the perfusion and adjust the flow rate until a steady state level is reached, usually between 500 and 1,200 mL/min.</li>
	<li>Insert three thermistors for temperature monitoring at three different locations: ingoing blood cannula, subcutaneously 15 cm above the knee joint, and subcutaneously 15 cm below the knee joint.</li>
	<li>If the foot has no tumor load, isolate it by wrapping an Esmarch tourniquet around it.</li>
	<li>To maintain temperature, wrap a sterile green drape around the leg to maintain temperature. Aim for a temperature of 39 C for the ingoing blood.</li>
</ol>
5. The perfusion (Figure 1)
<ol>
	<li>Inject a high dose of 100 MBq Tc99m marked albumin in the perfusion system. The leakage rate is now calculated by measuring the transference from this radiotracer between the systemic circulation and the circulation in the isolated limb.</li>
	<li>When a steady-state of the flow is established and no leakage is present, infuse melphalan at a dose of 10 mg/L limb volume for lower limbs and 13 mg/L limb volume for upper limbs during 10 min.</li>
	<li>For patients with sarcoma, bulky tumors, or re-perfusions, give TNF-alpha (1-4 mg) as a bolus dose 10-15 min before starting the melphalan infusion.</li>
	<li>After melphalan infusion, continue the perfusion for another 45 min.</li>
</ol>
6. End of the perfusion and vessel closure
<ol>
	<li>After a total perfusion time of 55 min or 65 min (in those patients treated with TNF-alpha), rinse the leg with 3 L of Ringers Acetate and massage the leg to help empty the venous reservoir.</li>
	<li>Disconnect the arterial and venous catheter from the perfusion system and remove the temperature probes and the Esmarch tourniquets.</li>
	<li>Remove the arterial catheter first and use the suture-mediated closure device to close the vessel.</li>
	<li>Remove the venous catheter and apply pressure to the groin for 5-10 min.</li>
</ol>
7. Postoperative care
<ol>
	<li>Extubate the patient and transfer them to the post-operative care unit for 4-6 h.</li>
	<li>Give thrombosis prophylaxis with Xarelto 10 mg for 4 weeks.</li>
	<li>Follow the patient up at the surgical outpatient department at 1-, 3- and 12-months post-operative to assess toxicities (according to the Wieberdink classification scale) and response rates.</li>
</ol>

<ol><li>Arnold, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Global+burden+of+cutaneous+melanoma+in+2020+and+projections+to+2040%5BTitle%5D)+AND+%22JAMA+Dermatol%22%5BJournal%5D)">Global burden of cutaneous melanoma in 2020 and projections to 2040.</a> JAMA Dermatol. 158 (5), 495-503 (2022).</li>
<li>Pawlik, T. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Predictors+and+natural+history+of+in-transit+melanoma+after+sentinel+lymphadenectomy%5BTitle%5D)+AND+%22Ann+Surg+Oncol%22%5BJournal%5D)">Predictors and natural history of in-transit melanoma after sentinel lymphadenectomy.</a> Ann Surg Oncol. 12 (8), 587-596 (2005).</li>
<li>Borgstein, P. J., Meijer, S., Van Diest, P. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Are+locoregional+cutaneous+metastases+in+melanoma+predictable%5BTitle%5D)+AND+%22Ann+Surg+Oncol%22%5BJournal%5D)">Are locoregional cutaneous metastases in melanoma predictable.</a> Ann Surg Oncol. 6 (3), 315-321 (1999).</li>
<li>Creech, O. Jr, Krementz, E. T., Ryan, R. F., Winblad, J. N. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Chemotherapy+of+cancer%3A+Regional+perfusion+utilizing+an+extracorporeal+circuit%5BTitle%5D)+AND+%22Ann+Surg%22%5BJournal%5D)">Chemotherapy of cancer: Regional perfusion utilizing an extracorporeal circuit.</a> Ann Surg. 148 (4), 616-632 (1958).</li>
<li>Olofsson, R., Mattsson, J., Lindner, P. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Long-term+follow-up+of+163+consecutive+patients+treated+with+isolated+limb+perfusion+for+in-transit+metastases+of+malignant+melanoma%5BTitle%5D)+AND+%22Int+J+Hyperthermia%22%5BJournal%5D)">Long-term follow-up of 163 consecutive patients treated with isolated limb perfusion for in-transit metastases of malignant melanoma.</a> Int J Hyperthermia. 29 (6), 551-557 (2013).</li>
<li>Raymond, A. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Current+trends+in+regional+therapy+for+melanoma%3A+Lessons+learned+from+225+regional+chemotherapy+treatments+between+1995+and+2010+at+a+single+institution%5BTitle%5D)+AND+%22J+Am+Coll+Surg%22%5BJournal%5D)">Current trends in regional therapy for melanoma: Lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution.</a> J Am Coll Surg. 213 (2), 306-316 (2011).</li>
<li>Beasley, G. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Isolated+limb+infusion+for+in-transit+malignant+melanoma+of+the+extremity%3A+A+well-tolerated+but+less+effective+alternative+to+hyperthermic+isolated+limb+perfusion%5BTitle%5D)+AND+%22Ann+Surg+Oncol%22%5BJournal%5D)">Isolated limb infusion for in-transit malignant melanoma of the extremity: A well-tolerated but less effective alternative to hyperthermic isolated limb perfusion.</a> Ann Surg Oncol. 15 (8), 2195-2205 (2008).</li>
<li>Kroon, H. M., Lin, D. Y., Kam, P. C., Thompson, J. F. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Safety+and+efficacy+of+isolated+limb+infusion+with+cytotoxic+drugs+in+elderly+patients+with+advanced+locoregional+melanoma%5BTitle%5D)+AND+%22Ann+Surg%22%5BJournal%5D)">Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma.</a> Ann Surg. 249 (6), 1008-1013 (2009).</li>
<li>Muilenburg, D. J., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Burden+of+disease+predicts+response+to+isolated+limb+infusion+with+melphalan+and+actinomycin+d+in+melanoma%5BTitle%5D)+AND+%22Ann+Surg+Oncol%22%5BJournal%5D)">Burden of disease predicts response to isolated limb infusion with melphalan and actinomycin d in melanoma.</a> Ann Surg Oncol. 22 (2), 482-488 (2015).</li>
<li>Huibers, A., Depalo, D. K., Perez, M. C., Zager, J. S., Olofsson Bagge, R. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. <a target="_blank" href="http://scholar.google.com/scholar?hl=en&safe=off&q=author%3aHuibers%2C+A+%22Clin+Exp+Metastasis%22">Clin Exp Metastasis</a>. , (2023).</li>
<li>Olofsson Bagge, R., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Minimally+invasive+isolated+limb+perfusion+-+technical+details+and+initial+outcome+of+a+new+treatment+method+for+limb+malignancies%5BTitle%5D)+AND+%22Int+J+Hyperthermia%22%5BJournal%5D)">Minimally invasive isolated limb perfusion - technical details and initial outcome of a new treatment method for limb malignancies.</a> Int J Hyperthermia. 35 (1), 667-673 (2018).</li>
<li>Dossett, L. A., Ben-Shabat, I., Olofsson Bagge, R., Zager, J. S. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/pubmed?term=((Clinical+response+and+regional+toxicity+following+isolated+limb+infusion+compared+with+isolated+limb+perfusion+for+in-transit+melanoma%5BTitle%5D)+AND+%22Ann+Surg+Oncol%22%5BJournal%5D)">Clinical response and regional toxicity following isolated limb infusion compared with isolated limb perfusion for in-transit melanoma.</a> Ann Surg Oncol. 23 (7), 2330-2335 (2016).</li>
</ol>

Roger Olofsson Bagge has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag), SkyLineDx and NeraCare GmbH, speaker honorarium from Roche, Pfizer and Pierre-Fabre, and has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Cansr.com, Merck Sharp &#38; Dohme (MSD), Novartis, Roche and Sanofi Genzyme, and is a shareholder in SATMEG Ventures AB.

Patients with ITM have a poor prognosis and their treatment remains challenging. A key factor in treating these patients is aiming for local control. In a minority of these patients, surgical excision can be used when the tumor load is limited. When patients have more extensive disease or when ITMs are rapidly recurring, surgical resection is not possible. In these patients, isolated limb perfusion is an effective treatment option, with a high overall response rate of around 80%10. Despite its hig...

The global incidence of melanoma is increasing and is particularly pronounced in the Western population, where one out of every 50 individuals will develop melanoma1. Patients with cutaneous melanoma can develop in-transit metastasis (ITM), most often localized to the limb2. These metastatic deposits appear as discrete tumor nodules within the subcutaneous or cutaneous tissue and arise between the primary melanoma site and the nearest regional lymph node basin. A compelling hypothesis implies that ITM develops after the entrapment and subsequent proliferation of tumor cell emboli in dermal lymphatic vessels between the primary tumor location and regional lymph nodules3. Surgical resection is an option for those patients with limited ITM, but when the tumor load is more extensive or when it is rapidly recurring, isolated limb perfusion (ILP) is an option.
ILP is an extremely effective regional treatment for advanced tumors but likely has no influence on the development of metastatic disease outside of the perfused region. The introduction of this technique dates back to 1958, when Creech and Krementz first described its principles4. The procedure consists of the isolation of the limb from the systemic circulation, achieved through the application of a pneumatic tourniquet or an Esmarch bandage, followed by its connection to an extracorporeal heart-lung machine. This allows for regional administration of heated chemotherapy (melphalan) at concentrations that would not be possible to give systemically5.
A minimally invasive counterpart is isolated limb infusion (ILI), where access is gained via percutaneous insertion of arterial and venous catheters via the contralateral groin. Subsequently, chemotherapy is then infused under tourniquet isolation in an ischemic environment for a duration of 20-30 min. Across various studies, overall tumor response rates for ILI and its counterpart ILP, have ranged between 40%-90%, whereas ILP generally yields higher response rates6,7,8,9,10. ILI offers several advantages, including the possibility of repeating it more easily, its percutaneous vascular access, and, therefore, potentially fewer adverse events, such as wound complications. Furthermore, it does not necessitate the use of an extracorporeal oxygenator.
In 2016, Sahlgrenska University Hospital developed a technique that combined both methods, minimally-invasive limb perfusion (MI-ILP), with the goal of performing isolated limb perfusion, but with the advantage of doing this in a minimally invasive setting. In this procedure, the femoral vessels are percutaneously accessed in a similar way as in ILP. In this paper, we present the technical details of the procedure, which is of special interest to clinicians who treat melanoma ITM and sarcoma.

<table><tbody><tr><td>0.018&amp;rdquo; introducer guidewire&amp;nbsp;</td><td></td><td></td><td></td></tr><tr><td>0.035&amp;rdquo; exchange guidewire&amp;nbsp;</td><td></td><td></td><td></td></tr><tr><td>10-12Fr BioMedicus Nextgen Pediatric Arterial cannulae.&amp;nbsp;</td><td>Medtronic, Minneapolis, MN, USA</td><td>96820-110 (10Fr); 96820-112 (12Fr)</td><td></td></tr><tr><td>12-14 Fr BioMedicus&amp;nbsp; NextGen Pediatric Venous Cannulae&amp;nbsp;</td><td>Medtronic, Minneapolis, MN, USA</td><td>96830-112 (12Fr); 96830-114 (14Fr)</td><td></td></tr><tr><td>Esmarch tourniquets&amp;nbsp;</td><td>McKesson&amp;nbsp;</td><td>16-50409</td><td></td></tr><tr><td>Micro-introducer, 4 Fr, 10 cm&amp;nbsp;</td><td>MAK, Merit Medical, USA&amp;nbsp;</td><td>MAK401&amp;nbsp;</td><td>Includes: (1) Co-axial introducer/dilator pair; (2) 21G Needle; (3) Guide wire</td></tr><tr><td>PerClose ProGlide closure devices</td><td>Abbott&amp;nbsp;</td><td>12773-02</td><td>Includes:&amp;nbsp; (1)Perclose Suture-Mediated Closure and repair device; (2) suture trimmer; (3) snared knot pusher&amp;nbsp;</td></tr><tr><td>Special Needle (20G, 12 cm)&amp;nbsp;</td><td>Mediplast AB, Sweden</td><td>662620091</td><td></td></tr></tbody></table>

minimally invasive isolated limb perfusion (mi-ilp) for locally advanced melanomas and sarcomas of the extremity

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Minimally invasive isolated limb perfusion (MI-ILP) is a treatment option for patients with locally advanced melanomas and sarcomas of the extremities. Briefly, the procedure starts with percutaneous access of the femoral or brachial vessels in the diseased extremity. It is then isolated from the rest of the body with a tourniquet. The catheters are connected to a heart-lung machine, and the extremity is perfused with a high dose of melphalan. In the literature, the reported overall and complete response rates for ILP are approximately 80% and 60%, respectively. Our previously reported results using MI-ILP, showed similar response rates. The objective of this manuscript is to provide a step-by-step guide on how to perform an MI-ILP. The purpose of this protocol is to enable local perfusion of the extremities with a high dose of chemotherapy without systemic leakage in a minimally invasive manner.

We have previously published the results of the first six patients treated with MI-ILP (five femoral and one brachial) between June 2016 and March 2017 at Sahlgrenska University Hospital11. Patients who were 18 years or older with a locally advanced tumor of the extremity that had an indication for ILP were included in the study. Patients were excluded if they had a previous lymph node dissection, current lymph node disease, or severe atherosclerosis, as this could potentially complicate percutane...

This protocol presents a step-by-step guide for performing minimally invasive isolated limb perfusion (MI-ILP), a treatment option for patients with locally advanced melanomas and sarcomas of the extremities.

Minimally invasive isolated limb perfusion (MI-ILP) is a treatment option for patients with locally advanced melanomas and sarcomas of the extremities. ...

minimally-invasive-isolated-limb-perfusion-mi-ilp-for-locally

Research

JoVE Journal

Medicine

The surgical procedure for induction of unilateral hindlimb ischemia is demonstrated, with confirmation of ischemia by laser Doppler perfusion imaging.

Murine Model of Hindlimb Ischemia 

We show here the in vivo insertion of an osmotic pump for constant local drug delivery and the creation of hindlimb ischemia in a mouse model. Moreover, the hindlimb vasculature is perfused with Microfil, a silicone radiopaque agent, to prepare for micro-computed tomography (micro-CT) imaging.

Osmotic Drug Delivery to Ischemic Hindlimbs and Perfusion of Vasculature with Microfil for Micro-Computed Tomography Imaging

Here, we present a protocol how to perform an isolated liver perfusion (IHP) with melphalan and we also discuss IHP as a treatment option for liver metastases of uveal melanoma.

Isolated Hepatic Perfusion as a Treatment for Liver Metastases of Uveal Melanoma

In this manuscript, we describe percutaneous isolated hepatic perfusion with simultaneous chemofiltration as treatment for unresectable liver metastases. This procedure is performed under general anaesthesia in the angiosuite by an experienced team, consisting of an interventional radiologist, a clinical perfusionist and anaesthesiologist.

Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver

Surgical induction of hindlimb ischemia in the mouse is useful to examine angiogenesis, however this is compromised in certain inbred mouse strains that display marked ischemia-induced tissue necrosis. Methods are described to induce subacute limb ischemia using ameroid constrictors to circumvent this problem through the induction of gradual arterial occlusion.

Methods for Acute and Subacute Murine Hindlimb Ischemia

Here, a critical hindlimb ischemia experimental model is presented followed by a battery of functional, histologic and molecular tests to assess the effectiveness of angiogenic...

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Lower limb amputation may occur even after angioplasty of obstructed vessels in Critical Limb Ischemia (CLI). Mononuclear Progenitor Cells (MPCs) reflect vascular repair. The present protocol describes the quantification of MPCs from circulation close to angioplasty, and its relationship with endothelial dysfunction and prediction of lower limb amputation.

Predicting Amputation using Local Circulating Mononuclear Progenitor Cells in Angioplasty-treated Patients with Critical Limb Ischemia

Here, we present a protocol that demonstrates the technique and necessary controls for Laser Doppler perfusion imaging to measure blood flow in the mouse hindlimb.

Laser Doppler Perfusion Imaging in the Mouse Hindlimb

The present protocol describes a unique, clinically relevant model of peripheral arterial disease that combines femoral artery and vein electrocoagulation with the administration of a nitric oxide synthase inhibitor to induce hindlimb gangrene in FVB mice. Intracardiac DiI perfusion is then used for high-resolution, three-dimensional imaging of the footpad vasculature.

High-Resolution Three-Dimensional Imaging of the Footpad Vasculature in a Murine Hindlimb Gangrene Model

A laser speckle contrast imaging system was used to monitor the changes in renal microvascular blood flow during unilateral renal ischemia-reperfusion after the resection of the right kidney in mice.

Microvascular Perfusion Monitored by Laser Speckle Contrast Imaging during Renal Ischemia-Reperfusion Injury in Mice

Learn minimally invasive isolated limb perfusion for treating advanced melanomas and sarcomas of the extremity using localized high-dose chemotherapy. This protocol demonstrates percutaneous vascular access and perfusion techniques.

Minimally Invasive Isolated Limb Perfusion (MI-ILP) for Locally Advanced Melanomas and Sarcomas of the Extremity

Explore More Videos